# Novel Smoking Cessation Drug for Schizophrenia

> **NCT02230384** · PHASE2 · COMPLETED · sponsor: **K.N. Roy Chengappa** · enrollment: 62 (actual)

## Conditions studied

- Smoking Cessation

## Interventions

- **DRUG:** Active JNJ Drug
- **DRUG:** Placebo Pill

## Key facts

- **NCT ID:** NCT02230384
- **Lead sponsor:** K.N. Roy Chengappa
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-12-16
- **Final completion:** 2017-03-09
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2019-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02230384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02230384, "Novel Smoking Cessation Drug for Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02230384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*